DK2637663T3 - Kombinationsterapi med et antitumor-alkaloid - Google Patents

Kombinationsterapi med et antitumor-alkaloid Download PDF

Info

Publication number
DK2637663T3
DK2637663T3 DK11781807.0T DK11781807T DK2637663T3 DK 2637663 T3 DK2637663 T3 DK 2637663T3 DK 11781807 T DK11781807 T DK 11781807T DK 2637663 T3 DK2637663 T3 DK 2637663T3
Authority
DK
Denmark
Prior art keywords
cancer
pharmaceutically acceptable
combination
acceptable salt
antimetabolite
Prior art date
Application number
DK11781807.0T
Other languages
English (en)
Inventor
Ocaña Victoria Moneo
Núñez Gema Santamaría
Fernández Luis Francisco García
Carlos María Galmarini
Navarro María José Guillén
Marín Pablo Manuel Avilés
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Application granted granted Critical
Publication of DK2637663T3 publication Critical patent/DK2637663T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (10)

1. PM01183 eller et farmaceutisk acceptabelt salt deraf til anvendelse til behandling af cancer, omfattende administration af en terapeutisk effektiv mængde PM01183 eller et farmaceutisk acceptabelt salt deraf i synergistisk kombination med en terapeutisk effektiv mængde af en antimetabolit, hvor antimetabolitten er valgt blandt 5-fluoruracil, gemcitabin, cytarabin, capecitabin, decitabin, floxuridin, aminopterin, methotrexat, pe-metrexed og raltitrexed.
2. PM01183 eller et farmaceutisk acceptabelt salt deraf til anvendelse til forøgelse af den terapeutiske effektivitet af en antimetabolit ved behandling af cancer, som omfatter administration til en patient, som har behov derfor, af en terapeutisk effektiv mængde PM01183 eller et farmaceutisk acceptabelt salt deraf i synergistisk kombination med antimetabolitten, hvor antimetabolitten er valgt blandt 5-fluoruracil, gemcitabin, cytarabin, capecitabin, decitabin, floxuridin, aminopterin, methotrexat, pemetrexed og raltitrexed.
3. PM01183 eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge krav 1 eller 2, hvor PM01183 eller et farmaceutisk acceptabelt salt deraf og antimetabolitten udgør en del af det samme lægemiddel.
4. PM01183 eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge krav 1 eller 2, hvor PM01183 eller et farmaceutisk acceptabelt salt deraf og antimetabolitten tilvejebringes som separate lægemidler til administration på samme tid eller på forskellige tidspunkter.
5. PM01183 eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge krav 4, hvor PM01183 eller et farmaceutisk acceptabelt salt deraf og antimetabolitten tilvejebringes som separate lægemidler til administration på forskellige tidspunkter.
6. PM01183 eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge et hvilket som helst af de foregående krav, hvor antimetabolitten er valgt blandt 5-fluoruracil, capecitabin, gemcitabin, cytarabin og methotrexat.
7. PM01183 eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge krav 6, hvor antimetabolitten er valgt blandt 5-fluoruracil, gemcitabin, cytarabin og methotrexat.
8. PM01183 eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge et hvilket som helst af de foregående krav, hvor den cancer, der skal behandles, er valgt blandt lungecancer, sarkom, malignt melanom, blærecarcinom, prostatacancer, carcinom i bugspytkirtlen, cancer i skjoldbruskkirtlen, gastrisk carcinom, ovariecancer, hepatom, brystcancer, colorektal cancer, nyrecancer, cancer i spiserøret, neuroblastom, hjernecancer, livmoderhalscancer, anal cancer, testikelcancer, leukæmi, multipelt myelom og lymfom.
9. PM01183 eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge krav 8, hvor den cancer, der skal behandles, er valgt blandt lungecancer, sarkom, malignt melanom, prostatacancer, carcinom i bugspytkirtlen, gastrisk carcinom, ovariecancer, hepatom, brystcancer, colorektal cancer, nyrecancer, hjernecancer, leukæmi og lymfom.
10. Kit til anvendelse til behandling af cancer, som omfatter en doseringsform af PM01183 eller et farmaceutisk acceptabelt salt deraf; og en doseringsform af en antimetabolit, hvor antimetabolitten er valgt blandt 5-fluoruracil, gemcitabin, cytarabin, capecitabin, decitabin, floxuridin, aminopterin, methotrexat, pemetrexed og raltitrexed; og instruktioner til anvendelse af begge lægemidler i synergistisk kombination som beskrevet i et hvilket som helst af de foregående krav.
DK11781807.0T 2010-11-12 2011-11-11 Kombinationsterapi med et antitumor-alkaloid DK2637663T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10382300 2010-11-12
PCT/EP2011/069976 WO2012062920A1 (en) 2010-11-12 2011-11-11 Combination therapy with an antitumor alkaloid

Publications (1)

Publication Number Publication Date
DK2637663T3 true DK2637663T3 (da) 2016-04-18

Family

ID=44936282

Family Applications (4)

Application Number Title Priority Date Filing Date
DK11781807.0T DK2637663T3 (da) 2010-11-12 2011-11-11 Kombinationsterapi med et antitumor-alkaloid
DK14175268.3T DK2786754T3 (da) 2010-11-12 2011-11-11 Kombinationsterapi med en mitotisk inhibitor
DK14175259.2T DK2786753T3 (da) 2010-11-12 2011-11-11 Kombinationsterapi med et antitumorantibiotikum
DK14175282.4T DK2786756T3 (en) 2010-11-12 2011-11-11 Kombinationsterapi med en topoisomeraseinhibitor

Family Applications After (3)

Application Number Title Priority Date Filing Date
DK14175268.3T DK2786754T3 (da) 2010-11-12 2011-11-11 Kombinationsterapi med en mitotisk inhibitor
DK14175259.2T DK2786753T3 (da) 2010-11-12 2011-11-11 Kombinationsterapi med et antitumorantibiotikum
DK14175282.4T DK2786756T3 (en) 2010-11-12 2011-11-11 Kombinationsterapi med en topoisomeraseinhibitor

Country Status (24)

Country Link
US (5) US20130266666A1 (da)
EP (6) EP2786753B1 (da)
JP (4) JP6382516B2 (da)
KR (9) KR102301175B1 (da)
CN (3) CN105664165A (da)
AU (4) AU2011328004C1 (da)
BR (4) BR122017028566B1 (da)
CA (4) CA2995018C (da)
CY (4) CY1117466T1 (da)
DK (4) DK2637663T3 (da)
ES (4) ES2719091T3 (da)
HK (1) HK1202422A1 (da)
HR (4) HRP20160361T1 (da)
HU (4) HUE042801T2 (da)
LT (3) LT2786756T (da)
ME (3) ME02395B (da)
PL (4) PL2786754T3 (da)
PT (3) PT2786756T (da)
RS (4) RS54648B1 (da)
RU (4) RU2605335C2 (da)
SI (4) SI2786753T1 (da)
SM (4) SMT201900190T1 (da)
TR (2) TR201903859T4 (da)
WO (1) WO2012062920A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
RS54648B1 (sr) * 2010-11-12 2016-08-31 Pharma Mar S.A. Kombinovana terapija sa antitumorskim alkaloidom
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
KR101588949B1 (ko) * 2014-03-13 2016-01-29 아주대학교산학협력단 플루나리진을 유효성분으로 함유하는 뇌암에 대한 항암 활성 보조제
US11326210B2 (en) * 2015-01-30 2022-05-10 Glax Llc Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer
CA3239447A1 (en) * 2016-01-11 2017-07-20 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
KR102491180B1 (ko) 2017-04-27 2023-01-20 파르마 마르 에스.에이. 항종양 화합물
JP2022512826A (ja) 2018-10-26 2022-02-07 シンデブルックス，インコーポレイティド ＭｅｔＡＰ２阻害剤のバイオマーカーとその応用
CA3148690A1 (en) * 2019-09-03 2021-03-11 Ioannis METAXAS Lurbinectedin in the treatment of malignant mesothelioma
KR20210049403A (ko) * 2019-10-25 2021-05-06 연세대학교 산학협력단 암의 예방 또는 치료용 조성물
PE20252386A1 (es) * 2019-11-21 2025-10-10 Pharma Mar Sa Metodo de tratamiento del cancer de pulmon de celulas pequenas con formulaciones de lurbinectedina
WO2021228414A1 (en) * 2020-05-14 2021-11-18 Pharma Mar, S.A. Methods of treating small cell lung cancer with lurbinectedin formulations
MA56827B2 (fr) * 2019-11-21 2023-09-27 Pharma Mar Sa Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine
CN111298122B (zh) * 2019-12-04 2021-12-21 哈尔滨商业大学 用于治疗小细胞肺癌的药物组合物及其应用
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
CN113491771A (zh) * 2020-03-18 2021-10-12 苏州大学 小分子化合物在制备glut5摄取转运果糖的抑制剂中的应用
EP4141110A4 (en) 2020-04-24 2025-04-09 Sf Biotech Laboratuvar Danismanlik Anonim Sirketi Method for producing particles of bacteriophages of the genus levivirus
EP4176880A4 (en) * 2020-07-01 2024-07-03 New Cancer Cure - Bio Co., Ltd. PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER COMPRISING A 3-KETOACYL-COA THIOLASE INHIBITOR AND AN INHIBITOR OF CARNITINE ACYLCARNITINE TRANSPORTERS
CN118576611A (zh) * 2020-10-23 2024-09-03 和记黄埔医药（上海）有限公司 一种药物组合产品在制备用于治疗尤文氏肉瘤的药物中的用途
CN112870194B (zh) * 2021-01-06 2022-06-21 广州医科大学附属肿瘤医院 治疗肝癌的组合物及其应用
CN113633631B (zh) * 2021-06-17 2022-08-09 中国医学科学院医药生物技术研究所 米铂脂质体在抗耐药性肿瘤的应用
CN115246846B (zh) * 2021-11-19 2024-10-01 江苏慧聚药业股份有限公司 卢比替定新晶型及其制备
WO2023165603A1 (en) * 2022-03-03 2023-09-07 Zai Lab (Shanghai) Co., Ltd. Dna-pk inhibitor and combination use thereof
WO2024188978A1 (en) * 2023-03-10 2024-09-19 Pharma Mar, S.A. Lurbinectedin as mcl-1 inhibitor and combinations thereof for use in treating cancer
EP4563149A1 (en) * 2023-11-30 2025-06-04 Pharma Mar, S.A. Lurbinectedin, ecubectedin and a related compound for use in the treatment of skin cancers
WO2025228596A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Combination of pm14 and a topoisomerase i inhibitor in the treatment of cancer
TW202547488A (zh) 2024-04-30 2025-12-16 西班牙商瑪製藥股份有限公司 於癌症的治療中之化合物Ｉａ和拓樸異構酶Ｉ抑制劑的組合

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
EP0309477B1 (en) 1986-06-09 1991-11-06 The Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
BR9909488B1 (pt) 1998-04-06 2011-02-08 ecteinascidinas semi-sintéticas e composição farmacêutica.
CA2331593C (en) 1998-05-11 2008-08-05 Pharma Mar, S.A. Metabolites of ecteinascidin 743
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
AR035842A1 (es) 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
CA2397597A1 (en) 2000-01-19 2001-07-26 The Trustees Of Columbia University In The City Of New York Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof
WO2001077115A1 (en) 2000-04-12 2001-10-18 Pharma Mar, S.A. Antitumoral ecteinascidin derivatives
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
BR0115162A (pt) * 2000-11-06 2003-10-21 Pharma Mar Sa Tratamentos antitumorais eficazes
SE0102232L (sv) 2001-06-25 2003-02-06 Anoto Ab Förfarande och anordning i ett digitalt kommunikationssystem
GB0119243D0 (en) * 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
AU2003250483A1 (en) 2002-08-19 2004-03-11 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
EP1572726B1 (en) 2002-10-18 2010-12-08 Pharma Mar, S.A.U. 4-methylhexanoic kahalalide f compound
FR2856688B1 (fr) 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
US7393277B2 (en) * 2003-08-25 2008-07-01 Igt Horseshoe payline system and games using that system
HRP20080598T3 (en) * 2003-11-13 2009-01-31 Pharma Mar Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
AU2004291037A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
MXPA06013902A (es) * 2004-05-28 2007-01-26 Pfizer Prod Inc Procedimiento para tratar el crecimiento de celulas anormal.
ATE368461T1 (de) 2004-10-29 2007-08-15 Pharma Mar Sa Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
CN101080227B (zh) * 2004-12-15 2011-08-31 诺瓦提斯公司 用于治疗癌症的治疗剂的组合
TW200744603A (en) * 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
WO2007101235A2 (en) * 2006-02-28 2007-09-07 Pharma Mar, S.A. Improved antitumoral treatments
JP2011520921A (ja) * 2008-05-16 2011-07-21 ファルマ・マール・ソシエダード・アノニマ 抗腫瘍アルカロイドとの併用療法
RS54648B1 (sr) * 2010-11-12 2016-08-31 Pharma Mar S.A. Kombinovana terapija sa antitumorskim alkaloidom

Also Published As

Publication number Publication date
PL2786754T3 (pl) 2019-07-31
PT2786754T (pt) 2019-04-24
KR20170096065A (ko) 2017-08-23
AU2017276155B2 (en) 2019-03-07
ES2719091T3 (es) 2019-07-08
KR102452022B1 (ko) 2022-10-06
KR20170124641A (ko) 2017-11-10
US20180078550A1 (en) 2018-03-22
HRP20200696T1 (hr) 2020-07-24
HK1202421A1 (en) 2015-10-02
BR112013011480A2 (pt) 2016-08-09
CN103282037B (zh) 2017-04-05
RU2605335C2 (ru) 2016-12-20
KR102301175B1 (ko) 2021-09-10
HUE042802T2 (hu) 2019-07-29
SI2786754T1 (sl) 2019-05-31
EP2786753B1 (en) 2019-01-09
RU2018102078A (ru) 2019-07-19
JP6724055B2 (ja) 2020-07-15
TR201904459T4 (tr) 2019-05-21
RS58608B1 (sr) 2019-05-31
HUE027516T2 (en) 2016-10-28
ES2790414T3 (es) 2020-10-27
CA2817420C (en) 2019-09-24
EP2637663B1 (en) 2016-02-24
JP2016138133A (ja) 2016-08-04
RU2016144668A3 (da) 2020-03-25
CN105664165A (zh) 2016-06-15
DK2786756T3 (en) 2020-04-27
BR122017028568B1 (pt) 2022-03-03
RS54648B1 (sr) 2016-08-31
US20230404999A1 (en) 2023-12-21
US20130266666A1 (en) 2013-10-10
EP2786753A2 (en) 2014-10-08
RS58609B1 (sr) 2019-05-31
US11590129B2 (en) 2023-02-28
ME03408B (me) 2020-01-20
PT2786756T (pt) 2020-05-07
KR20210046853A (ko) 2021-04-28
AU2017276157A1 (en) 2018-01-04
KR20170057472A (ko) 2017-05-24
CA2995025A1 (en) 2012-05-18
CY1121504T1 (el) 2020-05-29
EP3666275A2 (en) 2020-06-17
AU2011328004C1 (en) 2017-01-19
JP2018100302A (ja) 2018-06-28
JP6382516B2 (ja) 2018-08-29
ES2719052T3 (es) 2019-07-08
SI2786756T1 (sl) 2020-07-31
RU2018102080A3 (da) 2021-04-12
EP2786754A3 (en) 2014-10-29
KR20170058454A (ko) 2017-05-26
LT2786753T (lt) 2019-04-10
CA2995033C (en) 2020-04-28
RU2018102078A3 (da) 2021-04-20
ME02395B (me) 2016-09-20
RU2013126630A (ru) 2014-12-20
KR20190130078A (ko) 2019-11-20
TR201903859T4 (tr) 2019-04-22
PT2786753T (pt) 2019-04-24
SI2786753T1 (sl) 2019-05-31
PL2786753T3 (pl) 2019-09-30
HRP20190565T1 (hr) 2019-05-17
ME03501B (me) 2020-04-20
BR122017028566B1 (pt) 2022-03-03
US20180008602A1 (en) 2018-01-11
JP2018100303A (ja) 2018-06-28
KR102247982B1 (ko) 2021-05-04
RU2016144668A (ru) 2018-12-18
CA2995018A1 (en) 2012-05-18
CY1117466T1 (el) 2017-04-26
RU2018102080A (ru) 2019-07-19
JP6723815B2 (ja) 2020-07-15
US20180078551A1 (en) 2018-03-22
SMT201600112B (it) 2016-07-01
RU2743643C2 (ru) 2021-02-20
EP2637663A1 (en) 2013-09-18
HK1202423A1 (en) 2015-10-02
HRP20190554T1 (hr) 2019-05-03
HK1202419A1 (en) 2015-10-02
HK1202422A1 (en) 2015-10-02
KR101716804B1 (ko) 2017-03-15
PL2786756T3 (pl) 2020-07-13
KR20160088956A (ko) 2016-07-26
AU2011328004A1 (en) 2013-05-30
EP2786754A2 (en) 2014-10-08
CN106860870B (zh) 2020-03-31
SMT201900190T1 (it) 2019-05-10
BR122017028570B1 (pt) 2022-03-03
JP6724056B2 (ja) 2020-07-15
AU2017276155A1 (en) 2018-01-04
CN106860870A (zh) 2017-06-20
HUE049389T2 (hu) 2020-09-28
CA2995033A1 (en) 2012-05-18
EP2786756B1 (en) 2020-03-11
EP2786753A3 (en) 2014-10-29
HRP20160361T1 (hr) 2016-05-06
EP2786755A3 (en) 2014-10-29
EP2786756A2 (en) 2014-10-08
PL2637663T3 (pl) 2016-08-31
SMT202000211T1 (it) 2020-05-08
CA2995025C (en) 2020-04-28
CA2995018C (en) 2021-04-20
RU2757373C2 (ru) 2021-10-14
EP3666275A3 (en) 2020-09-09
CA2817420A1 (en) 2012-05-18
LT2786756T (lt) 2020-05-11
AU2011328004B2 (en) 2016-07-14
SMT201900186T1 (it) 2019-05-10
BR112013011480A8 (pt) 2018-01-02
WO2012062920A1 (en) 2012-05-18
JP2013542241A (ja) 2013-11-21
ES2569180T3 (es) 2016-05-09
RU2767664C2 (ru) 2022-03-18
DK2786754T3 (da) 2019-04-15
DK2786753T3 (da) 2019-04-15
RS60236B1 (sr) 2020-06-30
CY1121501T1 (el) 2020-05-29
EP2786754B1 (en) 2019-01-09
EP2786755A2 (en) 2014-10-08
BR112013011480B1 (pt) 2022-03-22
SI2637663T1 (sl) 2016-05-31
EP2786756A3 (en) 2014-10-29
HK1188572A1 (zh) 2014-05-09
AU2016200191A1 (en) 2016-02-04
HUE042801T2 (hu) 2019-07-29
AU2017276157B2 (en) 2019-03-07
LT2786754T (lt) 2019-04-10
AU2016200191B2 (en) 2018-01-18
CN103282037A (zh) 2013-09-04
CY1122904T1 (el) 2021-10-29
KR20130140071A (ko) 2013-12-23
KR20170096224A (ko) 2017-08-23

Similar Documents

Publication Publication Date Title
DK2637663T3 (da) Kombinationsterapi med et antitumor-alkaloid
HK1188572B (en) Combination therapy with an antitumor alkaloid
HK1202421B (en) Combination therapy with an antitumor antibiotic
HK1202423B (en) Combination therapy with a topoisomerase inhibitor
HK1202419B (en) Combination therapy with a mitotic inhibitor